Melinta Therapeutics Inc., of New Haven, Conn., said it has begun an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $75 million. The company intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares on the same terms and conditions. The net proceeds will be used for general corporate purposes, including investing in its portfolio of antibiotics.